The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer
Chemotherapy · 2025
DOI: 10.1159/000543425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemotherapy, 2025. Verfasst von Daiki Murata und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan. Hauptthemen laut MEDLINE: Ghrelin, Cachexia, Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Introduction
Identifying the underlying mechanisms of immune checkpoint inhibitor resistance in patients with cachexia is a current challenge. Ghrelin is a peptide hormone that plays an important role in the metabolism of patients with cancer cachexia. Despite the importance of ghrelin in cancer cachexia, most previous studies on the subject have not distinguished between the forms of ghrelin.
Methods
We retrospectively screened patients with advanced or recurrent non-small cell lung cancer receiving PD-1/PD-L1 inhibitor monotherapy. Active and inactive ghrelin levels were measured in 100 patients with available plasma samples at immune checkpoint inhibitor initiation. Cancer cachexia was defined as weight loss of at least 5% during the past 6 months or weight loss of at least 2% with a BMI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
- Biostatistics Center, Kurume University School of Medicine, Fukuoka, Japan.
- Department of Diagnostic Pathology, Kurume University Hospital, Fukuoka, Japan.
- Cancer Vaccine and Immunotherapy Center and Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Zitieren
APA
Murata, D., Azuma, K., Nishii, Y., Murotani, K., Matama, G., Kawahara, A., Tokito, T., Sasada, T., Hoshino, T., & Azuma, K. (2025). The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer. Chemotherapy. https://doi.org/10.1159/000543425
Vancouver
Murata D, Azuma K, Nishii Y, Murotani K, Matama G, Kawahara A, et al. The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer. Chemotherapy. 2025. doi:10.1159/000543425
BibTeX
@article{Murata2025,
author = {Murata, Daiki and Azuma, Koichi and Nishii, Yuuya and Murotani, Kenta and Matama, Goushi and Kawahara, Akihiko and Tokito, Takaaki and Sasada, Tetsuro and Hoshino, Tomoaki and Azuma, Koichi},
title = {The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer},
journal = {Chemotherapy},
year = {2025},
doi = {10.1159/000543425}
}
EUVIMED